Cargando…

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy

BACKGROUND: Strategies to reinvigorate exhausted T cells have achieved great efficacy in certain subpopulations of tumor patients. Blocking the antibodies that target programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 induces durable responses in Hodgkin’s lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuang, Zhihui, Li, Li, Zhang, Pan, Chen, Bingliang, Wu, Min, Ni, Haiqing, Yi, Shuai, Zou, Jia, Liu, Junjian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990255/ https://www.ncbi.nlm.nih.gov/pubmed/33928230 http://dx.doi.org/10.1093/abt/tbaa022

Ejemplares similares

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
por: Dayoub, Adam S., et al.
Publicado: (2020)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
por: Du, Wenwen, et al.
Publicado: (2017)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
por: Sauer, Natalia, et al.
Publicado: (2023)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

Tim-3 finds its place in the cancer immunotherapy landscape
por: Acharya, Nandini, et al.
Publicado: (2020)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021)

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
por: Schwartz, Stephanie, et al.
Publicado: (2022)

A mutagenesis analysis of Tim50, the major receptor of the TIM23 complex, identifies regions that affect its interaction with Tim23
por: Dayan, Dana, et al.
Publicado: (2019)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
Publicado: (2023)

Tim50’s presequence receptor domain is essential for signal driven transport across the TIM23 complex
por: Schulz, Christian, et al.
Publicado: (2011)

Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
por: Yang, Liu, et al.
Publicado: (2021)

Cardiolipin mediates membrane and channel interactions of the mitochondrial TIM23 protein import complex receptor Tim50
por: Malhotra, Ketan, et al.
Publicado: (2017)

Suppression of Allograft Rejection by Tim-1-Fc through Cross-Linking with a Novel Tim-1 Binding Partner on T Cells
por: Xiao, Liang, et al.
Publicado: (2011)

Tim Burton /
por: Marcos Arza, Marcos
Publicado: (2007)

Tim Lou
por: Lou, Hou Keong
Publicado: (2009)

The Small Toxic Salmonella Protein TimP Targets the Cytoplasmic Membrane and Is Repressed by the Small RNA TimR
por: Andresen, Liis, et al.
Publicado: (2020)

Tim1 and Tim3 are not essential for experimental allergic asthma
por: Barlow, J L, et al.
Publicado: (2011)

Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
por: Hervas-Stubbs, Sandra, et al.
Publicado: (2015)

Down-Regulation of Tim-3 in Monocytes and Macrophages in Plasmodium Infection and Its Association with Parasite Clearance
por: Hou, Nan, et al.
Publicado: (2017)

Tim-4 Inhibits NO Generation by Murine Macrophages
por: Xu, Li-yun, et al.
Publicado: (2015)

TIM-Finder: A new method for identifying TIM-barrel proteins
por: Si, Jing-Na, et al.
Publicado: (2009)

Mertk Interacts with Tim-4 to Enhance Tim-4-Mediated Efferocytosis
por: Moon, Byeongjin, et al.
Publicado: (2020)

The structure of Tim50(164–361) suggests the mechanism by which Tim50 receives mitochondrial presequences
por: Li, Jingzhi, et al.
Publicado: (2015)

Altered expression of Tim family molecules and an imbalanced ratio of Tim-3 to Tim-1 expression in patients with type 1 diabetes
por: Liu, Yikai, et al.
Publicado: (2022)

Cancer cell intrinsic TIM-3 induces glioblastoma progression
por: Guo, Qing, et al.
Publicado: (2022)

TIM-3 Does Not Act as a Receptor for Galectin-9
por: Leitner, Judith, et al.
Publicado: (2013)

Interview with Tim Smith
por: Smith, Tim, et al.
Publicado: (2019)

Tim Berners-Lee
Publicado: (2004)

Come on, Sir Tim!
Publicado: (2009)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation
por: Zang, Kui, et al.
Publicado: (2021)

Divergent Small Tim Homologues Are Associated with TbTim17 and Critical for the Biogenesis of TbTim17 Protein Complexes in Trypanosoma brucei
por: Smith, Joseph T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9fm28pu426uqbb7e4o5l98fqdj